Unlike EDC systems, Clinical Ink’s SureSource® platform captures trial data electronically during the patient visit to dramatically reduce costs and development timelines

MOUNTAIN VIEW, Calif. – 3 SEPTEMBER – Based on its recent analysis of the eClinical solutions market, Frost & Sullivan recognizes Clinical Ink with the 2014 North American eClinical Solutions  Award for Entrepreneurial Company of the Year. The award recognizes Clinical Ink’s innovative SureSource® platform — the  first purpose-built eSource solution that captures data electronically at the point of care.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in devising a strong growth strategy and robustly implementing it. The recipient has shown strength in terms of innovation in products and technologies, leadership in customer value, as well as speed in response to market needs.  In short, the award looks at the emerging market players in the industry and recognizes best practices that are positioned to fundamentally impact the clinical development process.

“The intuitive SureSource platform offers the freedom to work without regard to connectivity, while allowing fast and secure electronic transmission of source documents and data,” said Jennifer Lazar, Frost & Sullivan Global Program Director, Life Sciences. “Clinical Ink’s client and user satisfaction has been extremely positive, with nearly 80 percent of users claiming that SureSource positively affected their clinical trial process and that they are eager to use it again.”

Clinical Ink is well-positioned to realize the FDA’s vision of eliminating paper in the clinical trial process (FDA’s recently released eSource guidance clearly “promotes” and “encourages” capturing data electronically).  The SureSource platform has been used in more than 50 studies worldwide and early adoption metrics show dramatic reductions in critical timelines and the potential to reduce monitoring cost by up to 50 percent.

Unlike existing electronic data capture (EDC) platforms, SureSource allows site users to immediately capture data during the subject visit, using a tablet equipped with custom-built electronic source (eSource) forms.  Reflecting the clinical workflow of sites, SureSource eSource forms look just like traditional paper source, but incorporate sophisticated data validations and safeguards to clean data at the time it is initially captured.  The clinical data is immediately available for real-time, remote review by sites, sponsors, and CROs – a dramatic improvement from the weeks/months it can take in the traditional EDC model.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Clinical Ink

With offices in Winston-Salem, NC and Philadelphia, PA, Clinical Ink is an innovation-driven eSource solutions company committed to delivering technology that makes clinical research easier for sites, sponsors, subjects and regulators.  Developers of SureSource®, the first purpose-built eSource platform that provides cleaner data faster, Clinical Ink is dedicated to eliminating paper documents in clinical research.  Additional information about Clinical Ink is available at http://www.clinicalink.com/ or by calling toll-free 800-301-5033.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.

Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.

Share This
X